These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 16632238)

  • 1. Comparison of the antioxidant and vascular effects of gliclazide and glibenclamide in Type 2 diabetic patients: a randomized crossover study.
    Shimabukuro M; Higa N; Takasu N
    J Diabetes Complications; 2006; 20(3):179-83. PubMed ID: 16632238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Forearm vascular reactivity is differentially influenced by gliclazide and glibenclamide in chronically treated type 2 diabetic patients.
    Wascher TC; Boes U
    Clin Physiol Funct Imaging; 2005 Jan; 25(1):40-6. PubMed ID: 15659079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diabetic endothelial dysfunction: effect of free radical scavenging in Type 2 diabetic patients.
    De Mattia G; Laurenti O; Fava D
    J Diabetes Complications; 2003; 17(2 Suppl):30-5. PubMed ID: 12623166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sulfonylurea treatment of type 2 diabetic patients does not reduce the vasodilator response to ischemia.
    Spallarossa P; Schiavo M; Rossettin P; Cordone S; Olivotti L; Cordera R; Brunelli C
    Diabetes Care; 2001 Apr; 24(4):738-42. PubMed ID: 11315840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular effects of glibenclamide vs. glimepiride and metformin in Type 2 diabetic patients.
    Abbink EJ; Pickkers P; Jansen van Rosendaal A; Lutterman JA; Tack CJ; Russel FG; Smits P
    Diabet Med; 2002 Feb; 19(2):136-43. PubMed ID: 11874430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics of pancreatic beta-cell secretion in Type 2 diabetic patients treated with gliclazide and glibenclamide.
    van der Wal PS; Heine RJ
    Diabetes Res Clin Pract; 2001 May; 52(2):103-11. PubMed ID: 11311964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glibenclamide vs gliclazide in reducing oxidative stress in patients of noninsulin dependent diabetes mellitus--a double blind randomized study.
    Chugh SN; Dhawan R; Kishore K; Sharma A; Chugh K
    J Assoc Physicians India; 2001 Aug; 49():803-7. PubMed ID: 11837468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of gliclazide and glibenclamide treatment in non-insulin-dependent diabetes.
    Baba S; Nakagawa S; Takebe K; Goto Y; Maezawa H; Takeda R; Sakamoto N; Fukui I
    Tohoku J Exp Med; 1983 Dec; 141 Suppl():693-706. PubMed ID: 6440313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.
    Wang JS; Lin SD; Lee WJ; Su SL; Lee IT; Tu ST; Tseng YH; Lin SY; Sheu WH
    Clin Ther; 2011 Dec; 33(12):1932-42. PubMed ID: 22078152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of glibenclamide on blood pressure and cardiovascular responsiveness in non-insulin dependent diabetes mellitus.
    Williams S; Abbott D; Morfis L; Manwaring P; Diamond T; Howes LG
    J Hypertens; 1998 May; 16(5):705-11. PubMed ID: 9797183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metformin or gliclazide, rather than glibenclamide, attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes.
    Katakami N; Yamasaki Y; Hayaishi-Okano R; Ohtoshi K; Kaneto H; Matsuhisa M; Kosugi K; Hori M
    Diabetologia; 2004 Nov; 47(11):1906-13. PubMed ID: 15565373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of gliclazide and left ventricular mass in type 2 diabetic patients.
    Pan NH; Lee TM; Lin MS; Huang CL; Chang NC
    Diabetes Res Clin Pract; 2006 Nov; 74(2):121-8. PubMed ID: 16631274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of gliclazide on platelet aggregation and the plasminogen activator inhibitor type 1 level in patients with type 2 diabetes mellitus.
    Konya H; Hasegawa Y; Hamaguchi T; Satani K; Umehara A; Katsuno T; Ishikawa T; Miuchi M; Kohri K; Suehiro A; Kakishita E; Miyagawa J; Namba M
    Metabolism; 2010 Sep; 59(9):1294-9. PubMed ID: 20070990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro and in vivo antioxidant properties of gliclazide.
    O'Brien RC; Luo M; Balazs N; Mercuri J
    J Diabetes Complications; 2000; 14(4):201-6. PubMed ID: 11004429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effects of glibenclamide and metformin on ambulatory blood pressure and cardiovascular reactivity in NIDDM.
    Sundaresan P; Lykos D; Daher A; Diamond T; Morris R; Howes LG
    Diabetes Care; 1997 May; 20(5):692-7. PubMed ID: 9135928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gliclazide improves anti-oxidant status and nitric oxide-mediated vasodilation in Type 2 diabetes.
    Fava D; Cassone-Faldetta M; Laurenti O; De Luca O; Ghiselli A; De Mattia G
    Diabet Med; 2002 Sep; 19(9):752-7. PubMed ID: 12207812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preventive and therapeutic effects of gliclazide on diabetic retinopathy: comparison with glibenclamide treatment.
    Minami N; Ikeda Y; Abe M
    Tohoku J Exp Med; 1983 Dec; 141 Suppl():707-11. PubMed ID: 6440314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glibenclamide vs gliclazide in type 2 diabetes of the elderly.
    Tessier D; Dawson K; Tétrault JP; Bravo G; Meneilly GS
    Diabet Med; 1994 Dec; 11(10):974-80. PubMed ID: 7895463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Daily blood glucose profiles of glibenclamide and gliclazide taken once or twice daily in elderly type 2 diabetic patients.
    Kigawa Y; Oba K; Futami-Suda S; Norose J; Yasuoka H; Suzuki K; Ouchi M; Watanabe K; Suzuki T; Nakano H
    Geriatr Gerontol Int; 2008 Sep; 8(3):160-5. PubMed ID: 18821999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute and short-term administration of a sulfonylurea (gliclazide) increases pulsatile insulin secretion in type 2 diabetes.
    Juhl CB; Pørksen N; Pincus SM; Hansen AP; Veldhuis JD; Schmitz O
    Diabetes; 2001 Aug; 50(8):1778-84. PubMed ID: 11473038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.